{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-040811","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.268142+00:00","generated_at":"2026-06-21T22:31:34.197989+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Femasys Q3 net loss widens to $2.98M; FemBloc trial enrollment complete, FemaSeed trial updated","bullets":["Q3 net loss $2.98M ($0.25/share) vs $2.26M ($0.19) YoY; revenue $347K (+28.9% on FemVue).","FemBloc Stage 2 enrollment complete; IDE for pivotal trial on track for Q1 2023.","FemaSeed trial updated to focus on male factor infertility; expects enrollment completion in 2023.","FemCerv commercially launched; FemCath expected by year-end.","Cash $16.0M at Sept 30, down from $24.8M at Dec 31, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-040811","json":"https://secwatch.observer/filing/0001140361-22-040811.json","markdown":"https://secwatch.observer/filing/0001140361-22-040811.md","text":"https://secwatch.observer/filing/0001140361-22-040811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036122040811/0001140361-22-040811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036122040811/brhc10043970_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:31:34.197989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f2c15aab8e0b1f3fd099ec26f4e7049929b33ff","claim":"FEMASYS INC reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Femasys Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036122040811/0001140361-22-040811-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}